Get Help Enrolling in the Immunotherapy – The Future of Mesothelioma Treatment? Clinical Trial

Writer

Matt Mauney is an award-winning journalist with nearly a decade of professional writing experience. He joined Asbestos.com in 2016, and he spends much of his time reading, analyzing and reporting on mesothelioma research articles to ensure people in the mesothelioma community know the latest medical advancements. Prior to joining Asbestos.com, Matt was a reporter at the Orlando Sentinel. Matt also edits some of the pages on the website. He also holds a certificate in health writing from the Centers for Disease Control and Prevention.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by

42 Cited Article Sources

  1. Calabro, L., Rossi, G. & Maio, M. (2018, January). New horizons from immunotherapy in malignant pleural mesothelioma.
    Retrieved from: http://jtd.amegroups.com/article/view/18245/html
  2. U.S. Food & Drug Administration. (2017, January-March). Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System.
    Retrieved from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm565425.htm
  3. Selecta Biosciences. (2018, March 12). Selecta Biosciences Announces First Patient Dosed In Phase 1 Trial Of SVP-Rapamycin And LMB-100 Combination Therapy In Mesothelioma.
    Retrieved from: https://www.thestreet.com/story/14518563/1/selecta-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-svp-rapamycin-and-lmb-100-combination-therapy-in-mesothelioma.html
  4. U.S. Food & Drug Administration. (2011, March). Yervoy (ipilimumab).
    Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
  5. ClinicalTrials.gov. (2017, December 14). Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma.
    Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02611037
  6. Institut für Diagnostische und Interventionelle Radiologie Uniklinik Frankfurt. (n.d.). Transarterial Chemoperfusion (TACP).
    Retrieved from: http://radiologie-uni-frankfurt.de/content/e6796/e13478/e13479/e13755/index_eng.html
  7. National Cancer Institute. (2017, May 4). Immunotherapy to Treat Cancer.
    Retrieved from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
  8. Leonard, J.P. et al. (2008, July). Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/18760704
  9. Selecta Biosciences. (n.d.). SEL-403 for Pancreatic Cancer and Mesothelioma.
    Retrieved from: http://selectabio.com/pipeline/mitigation-of-anti-drug-antibodies/oncology/
  10. McGinley, L. (2018, January 2). New cancer treatments have perplexing side effects.
    Retrieved from: https://www.washingtonpost.com/national/health-science/new-cancer-drugs-have-perplexing-side-effects/2018/01/02/9b84fa1e-d909-11e7-a841-2066faf731ef_story.html?utm_term=.4206c1a57e46
  11. Keytruda. (2017). Side Effects May Occur While Taking Keytruda.
    Retrieved from: https://www.keytruda.com/side-effects/
  12. Opdivo. (2017, October). What Should I Know About Potential Side Effects?
    Retrieved from: https://www.opdivo.com/advanced-nsclc/about-opdivo/side-effects
  13. Klampatsa, A. (2017, September). et al. Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615330/#sec7-cancers-09-00115title
  14. ClinicalTrials.gov. (2018, March 22). Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma.
    Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03436732?term=NCT03436732&rank=1
  15. Columbus, G. (2018, March 10). Immunotherapy Making Headway in SCLC and Mesothelioma.
    Retrieved from: http://www.onclive.com/conference-coverage/mlcc-2018/immunotherapy-making-headway-in-sclc-and-mesothelioma
  16. Welch, A. (2018, March 7). Brahmer Highlights Latest on Immunotherapy and Other Lung Cancer Advances.
    Retrieved from: http://www.onclive.com/conference-coverage/mlcc-2018/brahmer-highlights-latest-on-immunotherapy-and-other-lung-cancer-advances
  17. American Cancer Society. (2017, May 1). Immune checkpoint inhibitors to treat cancer.
    Retrieved from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html
  18. American Cancer Society. (2016, August 8). Monoclonal antibodies to treat cancer.
    Retrieved from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/monoclonal-antibodies.html
  19. American Cancer Society. (2016, August 8). What Is Cancer Immunotherapy?
    Retrieved from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html
  20. ClinicalTrials.gov. (2017, June 1). Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients.
    Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT02899299?term=opdivo+and+yervoy+and+mesothelioma
  21. Levitan, Dave. (2017, June 5). Immune Checkpoint Inhibition Shows Promise in Relapsing Malignant Pleural Mesothelioma. ASCO Daily News.
    Retrieved from: http://am.asco.org/immune-checkpoint-inhibition-shows-promise-relapsing-malignant-pleural-mesothelioma
  22. Penn Medicine News. Pembrolizumab Shows Promise in Treatment of Mesothelioma.
    Retrieved from: https://www.pennmedicine.org/news/news-releases/2017/march/pembrolizumab-shows-promise-in-treatment-of-mesothelioma
  23. ClinicalTrials.gov. (2018, March 13). Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743).
    Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT02899299?term=opdivo+and+yervoy+and+mesothelioma
  24. Caris Life Sciences. (2018). What are biomarkers?
    Retrieved from: https://www.mycancer.com/resources/what-are-biomarkers/
  25. U.S. Food & Drug Administration. (2015, October). Medication Guide: Keytruda.
    Retrieved from: https://www.fda.gov/downloads/drugs/drugsafety/ucm417493.pdf
  26. Christensen, S. (2018, March 20). Immunotherapy promising for cancer treatment, but Baltimore doctor warns of side effects.
    Retrieved from: http://baltimorepostexaminer.com/immunotherapy-promising-cancer-treatment-baltimore-doctor-warns-side-effects/2018/03/20
  27. Munson, P. et al. (2018, March 19). Exosomes from asbestos-exposed cells modulate gene expression in mesothelial cells.
    Retrieved from: http://www.fasebj.org/doi/10.1096/fj.201701291RR
  28. Maldarelli, C. (2017, August 30). The FDA just approved a game-changing cancer treatment.
    Retrieved from: https://www.popsci.com/car-t-cell-immunotherapy-cancer-FDA
  29. Cancer Research Institute. (n.d.). Timeline of Progress.
    Retrieved from: https://cancerresearch.org/immunotherapy/timeline-of-progress
  30. Morphotek. (n.d.). Amatuximab (MORAb-009).
    Retrieved from: http://www.morphotek.com/pipeline/Amatuximab.aspx
  31. Cancer Research Institute. (2017, December 9). Immunotherapy Patient Summit, Tampa.
    Retrieved from: https://www.cancerresearch.org/CRI/media/Files-for-download/Immunotherapy_Patient_Summit_Tampa_Deck.pdf
  32. The Merck Access Program. (2017, November). Keytruda (pembrolizumab).
    Retrieved from: https://www.merckaccessprogram-keytruda.com/hcp/
  33. National Cancer Institute. (2017, December 14). CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers.
    Retrieved from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
  34. AstraZeneca. (2017, July 27). AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer.
    Retrieved from: https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html
  35. Imfinzi (durvalumab). (2018, February). IMFINZI Is Now Approved for Unresectable Stage 3 Lung Cancer Following Chemoradiation Therapy.
    Retrieved from: https://www.imfinzi.com/stage-3-lung-cancer.html
  36. Harris, J. (2017, July 27). Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial.
    Retrieved from: http://www.onclive.com/web-exclusives/frontline-durvalumabtremelimumab-falls-short-in-phase-iii-nsclc-trial
  37. Selecta Biosciences. (2018, January). Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy.
    Retrieved from: https://globenewswire.com/news-release/2018/01/02/1277033/0/en/Selecta-Biosciences-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-LMB-100-and-SVP-Rapamycin-Combination-Therapy.html
  38. Gschmeissner, S. (2017, November 29). The Most Promising Cancer Treatments in a Century Have Arrived—But Not For Everyone.
    Retrieved from: https://www.wired.com/story/cancer-immunotherapy-has-arrived-but-not-for-everyone/
  39. Grady, D. (2012, December 9). In Girl’s Last Hope, Altered Immune Cells Beat Leukemia.
    Retrieved from: https://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html
  40. Park, A. (2016, March 24). What If Your Immune System Could Be Taught to Kill Cancer?
    Retrieved from: http://time.com/magazine/us/4270341/april-4th-2016-vol-187-no-12-u-s/
  41. Tontonoz, M. (2015, December 9). Understanding Jimmy Carter’s Surprise Cancer Turnaround: A Conversation with Jedd Wolchok.
    Retrieved from: https://www.mskcc.org/blog/understanding-jimmy-carter-s-surprise-turnaround-conversation-jedd-wolchok
  42. Grady, D. (2011, September 12). An Immune System Trained to Kill Cancer. Retrieved from: https://www.nytimes.com/2011/09/13/health/13gene.html?pagewanted=all&_r=0
Chat live with a patient advocate now loading spinner